Patents Assigned to AbbVie Biotechnology Ltd.
-
Patent number: 9180244Abstract: Exemplary embodiments provide wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates, for example, in a single bolus. Exemplary embodiments provide methods for assembling wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates. Exemplary embodiments provide methods for using wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates.Type: GrantFiled: April 21, 2011Date of Patent: November 10, 2015Assignee: AbbVie Biotechnology LtdInventors: Philip D. Anderson, Joseph F. Julian, Linas P. Laurusonis, Timothy Parmer, Travis Yoch, Samuel M. Jang, Sean Corrigan, Tomas Matusaitis, William Fienup, Chris Strahm
-
Patent number: 9114166Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: December 2, 2014Date of Patent: August 25, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 9102723Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: November 21, 2014Date of Patent: August 11, 2015Assignee: AbbVie Biotechnology LtdInventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9096666Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: November 21, 2014Date of Patent: August 4, 2015Assignee: AbbVie Biotechnology LtdInventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9090689Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: April 8, 2015Date of Patent: July 28, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
-
Patent number: 9086418Abstract: The invention provides a method for determining the efficacy of a TNF? inhibitor, such as a TNF? antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.Type: GrantFiled: February 25, 2011Date of Patent: July 21, 2015Assignee: ABBVIE BIOTECHNOLOGY LTD.Inventors: Walter P. Maksymowych, Robert L. Wong
-
Patent number: 9085619Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: GrantFiled: October 3, 2014Date of Patent: July 21, 2015Assignee: AbbVie Biotechnology LTD.Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe
-
Patent number: 9085620Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: April 8, 2015Date of Patent: July 21, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
-
Patent number: 9073987Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: May 30, 2014Date of Patent: July 7, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 9067992Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: December 8, 2014Date of Patent: June 30, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Patent number: 9061005Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2012Date of Patent: June 23, 2015Assignee: AbbVie Biotechnology LtdInventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
-
Patent number: 9017680Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: November 14, 2014Date of Patent: April 28, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 9017287Abstract: An injection device comprises a syringe extendible against a spring bias from a retracted position in a housing to a projecting injecting position. A spring biased plunger has collapsible elbows which, when the plunger is released, initially engage the end of the syringe to drive it to the projecting position, whereupon arresting of the syringe movement causes the elbows to collapse inside the syringe to allow the plunger to engage and drive the bung.Type: GrantFiled: December 17, 2013Date of Patent: April 28, 2015Assignee: AbbVie Biotechnology LtdInventors: Stephen Bicknell, Joseph F. Julian, William L. Rudzena
-
Patent number: 8999337Abstract: The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF? inhibitor.Type: GrantFiled: June 10, 2008Date of Patent: April 7, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: John R. Medich, Susan K. Paulson, Peter A. Noertersheuser
-
Patent number: 8992926Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: September 26, 2014Date of Patent: March 31, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 8986693Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: October 9, 2014Date of Patent: March 24, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
-
Patent number: 8974790Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: May 30, 2014Date of Patent: March 10, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 8969024Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.Type: GrantFiled: August 27, 2008Date of Patent: March 3, 2015Assignee: AbbVie Biotechnology LtdInventors: Zehra Kaymakcalan, Limin Xiong
-
Patent number: 8961974Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2014Date of Patent: February 24, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
-
Patent number: 8961973Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2014Date of Patent: February 24, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan